ctDNA-guided immunotherapy boost after chemotherapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative invasive breast cancer (ER-, PR-, and HER2-).
- Your breast cancer was stage II to III when first diagnosed.
- You received chemotherapy before surgery (neoadjuvant chemotherapy).
- Your ctDNA blood test is positive (at baseline and/or after chemotherapy or surgery).
- You can do regular follow-up blood tests about every 3 months for at least a year.
- Staging scans show no spread to distant organs (no distant metastasis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
This trial tests a new combination of targeted chemotherapy (sacituzumab govitecan) with immunotherapy (pembrolizumab) against standard chemotherapy for people with triple-negative breast cancer that has not spread. It is for those who have already started a specific chemotherapy and immunotherapy regimen and may qualify if their cancer is stage II or III.
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.